These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24382657)

  • 1. Risk of recurrence of ductal carcinoma in situ by oncotype Dx technology: some concerns.
    Lagios MD; Silverstein MJ
    Cancer; 2014 Apr; 120(7):1085. PubMed ID: 24382657
    [No Abstract]   [Full Text] [Related]  

  • 2. Oncotype DX DCIS score predicts recurrence.
    Cancer Discov; 2015 Feb; 5(2):OF3. PubMed ID: 25656901
    [No Abstract]   [Full Text] [Related]  

  • 3. Qualitative Radiogenomics: Association Between BI-RADS Calcification Descriptors and Recurrence Risk as Assessed by the Oncotype DX Ductal Carcinoma In Situ Score.
    Woodard GA; Price ER
    AJR Am J Roentgenol; 2019 Apr; 212(4):919-924. PubMed ID: 30714832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score.
    Knopfelmacher A; Fox J; Lo Y; Shapiro N; Fineberg S
    Mod Pathol; 2015 Sep; 28(9):1167-73. PubMed ID: 26111975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.
    D'Alfonso TM; van Laar RK; Vahdat LT; Hussain W; Flinchum R; Brown N; John LS; Shin SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):705-15. PubMed ID: 23774991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ.
    Stackievicz R; Paran H; Bernheim J; Shapira M; Weisenberg N; Kaufman T; Klein E; Gutman M
    Isr Med Assoc J; 2010 May; 12(5):290-5. PubMed ID: 20929083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings.
    Li H; Whitney J; Bera K; Gilmore H; Thorat MA; Badve S; Madabhushi A
    Breast Cancer Res; 2019 Oct; 21(1):114. PubMed ID: 31623652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclusion of tumor biology molecular markers to improve the ductal carcinoma in situ ipsilateral breast tumor recurrence nomogram predictability.
    Ballehaninna UK; Chamberlain RS
    J Clin Oncol; 2011 Feb; 29(4):e97-8; author reply e99. PubMed ID: 21172894
    [No Abstract]   [Full Text] [Related]  

  • 10. Nomogram for risk of relapse after breast-conserving surgery in ductal carcinoma in situ.
    Mazouni C; Delaloge S; Rimareix F; Garbay JR
    J Clin Oncol; 2011 Jan; 29(2):e44; author reply e45-6. PubMed ID: 21135281
    [No Abstract]   [Full Text] [Related]  

  • 11. Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins.
    MacDonald HR; Silverstein MJ; Mabry H; Moorthy B; Ye W; Epstein MS; Holmes D; Silberman H; Lagios M
    Am J Surg; 2005 Oct; 190(4):521-5. PubMed ID: 16164913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("clinging ductal carcinoma in situ"): a simulator of normal mammary epithelium.
    Moinfar F; Man YG; Bratthauer GL; Ratschek M; Tavassoli FA
    Cancer; 2000 May; 88(9):2072-81. PubMed ID: 10813719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipsilateral breast tumor recurrence after breast-conserving surgery for ductal carcinoma in situ.
    Fujita T
    Ann Surg; 2011 Jun; 253(6):1233; author reply 1233-4. PubMed ID: 21522008
    [No Abstract]   [Full Text] [Related]  

  • 14. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic behavior of in situ ductal carcinoma of the breast.
    Forouhar FA
    Ann Clin Lab Sci; 1999; 29(3):167-8. PubMed ID: 10440579
    [No Abstract]   [Full Text] [Related]  

  • 17. Margin status after breast-conserving treatment of breast cancer: how much free margin is enough?
    von Smitten K
    J Surg Oncol; 2008 Dec; 98(8):585-7. PubMed ID: 19072849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice.
    Gradishar WJ; Hansen NM; Susnik B
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-7. PubMed ID: 19536946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
    Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
    Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is excision alone adequate treatment for low-risk ductal carcinoma-in-situ of the breast?
    Solin LJ
    J Clin Oncol; 2006 Mar; 24(7):1017-9. PubMed ID: 16461780
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.